Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of tulisokibart in radiographic axial spondyloarthritis
NL-OMON60609Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing tulisokibart with placebo (2 arms). Primary endpoint: ASAS40 response at Week 16. Started Dec 2025; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON60609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60609.